Company news

AstraZeneca PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Imfinzi approved in EU for AEGEAN

April 4, 2025

Enhertu approved in EU in post-ET breast cancer

April 4, 2025

Calquence recommended for EU approval in 1L MCL

March 31, 2025

Imfinzi approved in the US for bladder cancer

March 31, 2025

AZN invests $2.5bn in Beijing R&D & manufacturing

March 21, 2025

Eneboparatide Phase III trial met primary endpoint

March 17, 2025

Imfinzi approved in EU for limited-stage SCLC

March 17, 2025

AstraZeneca to acquire EsoBiotec

March 17, 2025

Notice of AGM

March 7, 2025

Imfinzi improved EFS in early-stage gastric cancer

March 7, 2025

Imfinzi recommended for EU approval for AEGEAN

March 3, 2025

Enhertu recommended in EU in post-ET breast cancer

February 28, 2025

Camizestrant improved PFS in 1L HR+ breast cancer

February 26, 2025

Directorate Change

February 18, 2025

Imfinzi recommended for EU approval for LS-SCLC

February 3, 2025

Enhertu approved in US for breast cancer post ET

January 28, 2025

Dato-DXd approved in US for HR+ breast cancer

January 20, 2025

Calquence combination approved in US for 1L MCL

January 17, 2025

Dato-DXd NSQ NSCLC application withdrawn in EU

December 24, 2024

Tagrisso approved in EU based on LAURA trial

December 23, 2024

Imfinzi approved in US for limited-stage SCLC

December 5, 2024

AstraZeneca appoints Iskra Reic EVP International

December 4, 2024

Truqap improved rPFS in advanced prostate cancer

November 25, 2024

Tagrisso recommended for EU approval - LAURA

November 18, 2024

AstraZeneca invests $3.5 billion in US

November 12, 2024

KOMET Phase III trial met primary endpoint

November 12, 2024

Dato-DXd new BLA submitted, NSQ BLA withdrawn

November 12, 2024

9M and Q3 2024 Results

November 12, 2024

Tezspire nasal polyps trial met primary endpoints

November 8, 2024

AZN share price movement

November 5, 2024

AZN China President under investigation

October 30, 2024

Wainzua recommended for approval in the EU

October 21, 2024

AstraZeneca licenses lipid lowering Lp(a) asset

October 7, 2024

Tagrisso US approval in unresectable lung cancer

September 26, 2024

Fasenra recommended for EU approval in EGPA

September 23, 2024

Final OS results reported for TROPION-Breast01

September 23, 2024

FluMist approved for self-administration in US

September 20, 2024

Fasenra EGPA US FDA approval

September 18, 2024

Imfinzi approved in US for resectable lung cancer

August 16, 2024

AstraZeneca prices a €1.4bn bond offering

July 30, 2024

Stabilisation Notice - ASTRAZENECA

July 29, 2024

Calquence fixed-duration combo improved 1L CLL PFS

July 29, 2024

ODAC reviewed Imfinzi in resectable lung cancer

July 26, 2024

Half-year Report

July 25, 2024

Acquisition of Amolyt Pharma completed

July 15, 2024

Lynparza & Imfinzi positive CHMP in endometrial

July 1, 2024

Update on Imfinzi ADJUVANT BR.31 trial

June 25, 2024

Imfinzi improved EFS and OS in bladder cancer

June 25, 2024

Update on CAPItello-290 Phase III trial

June 18, 2024

Imfinzi approved in the US for endometrial cancer

June 17, 2024

← Newer news releases · Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 242 decks. Every deck is listed under its year.